Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
To the Editor: We write regarding a recent commentary by Markowitz and colleagues (1) concluding that the concept of treatment-resistant depression (TRD) predominantly focuses on psychopharmacotherapy, while psychotherapy is largely neglected. Highlighting the advantages of psychotherapy over psychopharmacotherapy in major depressive disorder and TRD, the inclusion of evidence-based psychotherapy into staging models and treatment algorithms was proposed.
We appreciate the authors’ appeal for a strong therapeutic alliance balancing realistic optimism with recognition of suffering, and we agree with the necessity of refining the definition and the term “treatment resistant depression” due to its ambiguous and stigmatizing character. However, we are reluctant to share the authors’ critical concerns and consequent recommendations raised in the context of the negligence of psychotherapy in clinical studies and treatment guidelines, which we deem precipitant in parts, as they are based on pivotal, but selected and partly nonrecent studies. Exemplarily, recent findings of the European Group for the Study of Resistant Depression (GSRD), one of the largest international consortiums investigating the underpinnings of TRD and related diagnostic, therapeutic, and preventive strategies (2), were not considered. This was surprising to us, since the GSRD’s definition for TRD, that was proven in 2,762 depressed in- and outpatients and adopted by the European Medicines Agency (the European counterpart of the U.S. Food and Drug Administration), has increasingly been utilized in a majority of international trials. This might be relevant especially regarding psychotherapy per se, which was examined in combination with psychopharmacotherapy by the GSRD but, importantly, did not show favorable outcomes over psychopharmacotherapy alone (3). The latter study contrasts with the commentary deeming psychotherapy comparably efficacious, and partly even superior to psychopharmacotherapy. Along with further evidence from the GSRD and other international studies, it emphasizes the fundamental role of the underlying neurobiological interrelationships in major depressive disorder, and especially TRD, which is more appropriately and effectively addressed by biological treatments, such as psychopharmacotherapy, which directly interferes with its underlying neurobiology and hence represents both the recommended first-line treatment and the therapeutic basis. Considering this evidence in context may widen the horizon of interpretation and the related clinical implications—particularly when the GSRD’s naturalistic, real-world study design allowing the presence of suicidality, psychotic features, and comorbidities, which were repeatedly associated with TRD—is taken into account. This contrasts with the most randomized-controlled trials investigating very selective and less severely ill patients, who are often far from the broad clinical routine.

References

1.
Markowitz JC, Wright JH, Peeters F, et al: The neglected role of psychotherapy for treatment-resistant depression. Am J Psychiatry 2022; 179:90–93
2.
Bartova L, Dold M, Kautzky A, et al: Results of the European Group for the Study of Resistant Depression (GSRD)—basis for further research and clinical practice. World J Biol Psychiatry 2019; 20:427–448
3.
Bartova L, Fugger G, Dold M, et al: Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder—evidence from the European Group for the Study of Resistant Depression. J Psychiatr Res 2021; 141:167–175

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 687

History

Received: 7 March 2022
Accepted: 4 April 2022
Published online: 1 September 2022
Published in print: September 2022

Keywords

  1. Depressive Disorders
  2. Major Depressive Disorder
  3. Psychopharmacology
  4. Psychotherapy
  5. Drug/Psychotherapy Combination
  6. Antidepressants
  7. Pharmacotherapy

Authors

Details

Lucie Bartova, M.D., Ph.D.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).
Gernot Fugger, M.D., Ph.D.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).
Markus Dold, M.D.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).
Alexander Kautzky, M.D., Ph.D.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).
Dan Rujescu, M.D.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).
Siegfried Kasper, M.D. [email protected]
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Bartova, Fugger, Dold, Kautzky, Rujescu, Kasper); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Bartova, Dold); Center for Brain Research, Medical University of Vienna, Vienna, Austria (Kasper).

Notes

Send correspondence to Dr. Kasper ([email protected]).

Competing Interests

Dr. Bartova has received travel grants and consultant and speaker honoraria from Angelini, Diagnosia, Dialectica, Janssen, Lundbeck, Medizin Medien Austria, Schwabe, and Universimed. Dr. Fugger has received consultant and speaker honoraria from Janssen. Dr. Dold has received travel grants and consultant and speaker honoraria from Medizin Medien Austria, Janssen, and Universimed. Dr. Rujescu has received grant and research support from Janssen and Lundbeck; he has served as a consultant or on advisory boards for Janssen and Rovi; and he has served on the speakers bureaus of Janssen and Pharmagenetix. Dr. Kasper has received grant and research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage, and Schwabe; and he has served on speakers bureaus for Aspen Farmaceutica S.A., Angelini, Biogen, Janssen, Lundbeck, Neuraxpharma, Recordati, Sage, Sanofi, Schwabe, Servier, and Sun Pharma.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share